MCID: SKN019
MIFTS: 71

Skin Melanoma

Categories: Cancer diseases, Ear diseases, Skin diseases

Aliases & Classifications for Skin Melanoma

MalaCards integrated aliases for Skin Melanoma:

Name: Skin Melanoma 12 54 15
Cutaneous Melanoma 12 6 15 17 71
Malignant Melanoma of Ear and/or External Auricular Canal 12
Malignant Melanoma of Skin of Trunk Except Scrotum 12
Malignant Melanoma of Skin of Lower Limb 12
Malignant Melanoma of Skin of Upper Limb 12
Melanoma, Cutaneous Malignant 44
Malignant Lower Limb Melanoma 12
Malignant Upper Limb Melanoma 12
Malignant Scalp Melanoma 12
Malignant Trunk Melanoma 12
Malignant Neck Melanoma 12
Malignant Ear Melanoma 12
Malignant Lip Melanoma 12
Melanoma 71

Classifications:



External Ids:

Disease Ontology 12 DOID:8923
ICD9CM 34 172.9
MeSH 44 C562393
NCIt 50 C3510
SNOMED-CT 67 269577007
ICD10 32 C43 C43.9
UMLS 71 C0025202 C0151779

Summaries for Skin Melanoma

Disease Ontology : 12 A skin cancer that has material basis in melanocytes.

MalaCards based summary : Skin Melanoma, also known as cutaneous melanoma, is related to melanoma, cutaneous malignant 1 and acral lentiginous melanoma, and has symptoms including pruritus and exanthema. An important gene associated with Skin Melanoma is NRAS (NRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are Signaling by GPCR and Apoptotic Pathways in Synovial Fibroblasts. The drugs Triamcinolone and Vindesine have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and t cells, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Skin Melanoma

Diseases related to Skin Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 603)
# Related Disease Score Top Affiliating Genes
1 melanoma, cutaneous malignant 1 33.8 TP53 PTEN NRAS MITF MC1R MAP2K1
2 acral lentiginous melanoma 32.9 PTEN NRAS MC1R KIT HRAS CDKN2A
3 melanoma in congenital melanocytic nevus 32.7 NRAS MITF MC1R KIT HRAS GNAQ
4 spitzoid melanoma 32.6 NRAS HRAS GNAQ GNA11 CDKN2A BRAF
5 melanoma 32.4 TP53 PTEN NRAS MITF MC1R MAP2K1
6 skin carcinoma 31.9 TP53 PTEN NRAS MITF MC1R MAP2K1
7 mucosal melanoma 31.7 NRAS MITF KIT GNAQ GNA11 CDKN2A
8 lentigo maligna melanoma 31.7 MITF MC1R
9 neuroblastoma 31.3 TP53 PTEN NRAS MAP2K1 KIT HRAS
10 nodular malignant melanoma 31.3 TP53 NRAS MITF MC1R KIT HRAS
11 squamous cell carcinoma 31.3 TP53 PTEN MAP2K1 HRAS ERBB2 CTNNB1
12 leukemia, chronic lymphocytic 31.3 TP53 PTEN NRAS HRAS ERBB2 CDK4
13 myeloma, multiple 31.3 TP53 PTEN NRAS KIT HRAS ERBB2
14 actinic keratosis 31.2 TP53 MITF MC1R HRAS CTNNB1 CDKN2A
15 spitz nevus 31.2 TP53 HRAS CDKN2A BRAF
16 ocular melanoma 31.2 NRAS MC1R KIT GNAQ GNA11 CDKN2A
17 pancreatic cancer 31.2 TP53 PTEN MAP2K1 HRAS ERBB2 CTNNB1
18 basal cell carcinoma 31.2 TP53 PTEN MC1R KIT CTNNB1 CDKN2A
19 kaposi sarcoma 31.1 TP53 MAP2K1 CDK4 AKT1
20 endometrial cancer 31.1 TP53 PTEN NRAS KIT HRAS ERBB2
21 keratosis, seborrheic 31.1 TP53 MC1R CDKN2A
22 diffuse large b-cell lymphoma 31.1 TP53 PTEN CDKN2A CDK4 AKT1
23 lymphoma, non-hodgkin, familial 31.1 TP53 NRAS MAP2K1 BRAF AKT1
24 gastrointestinal stromal tumor 31.1 TP53 PTEN KIT ERBB2 CDKN2A BRAF
25 in situ carcinoma 31.1 TP53 PTEN HRAS ERBB2 CTNNB1 CDKN2A
26 hemangioma 31.0 TP53 PTEN KIT GNAQ GNA11 CTNNB1
27 melanoma, uveal 31.0 TP53 PTEN NRAS MITF MC1R MAP2K1
28 malignant conjunctival melanoma 30.9 NRAS HRAS GNAQ GNA11
29 merkel cell carcinoma 30.9 TP53 KIT CTNNB1 CDKN2A
30 exanthem 30.9 KIT HRAS ERBB2 AKT1
31 adenocarcinoma 30.9 TP53 PTEN MAP2K1 KIT HRAS ERBB2
32 rhabdomyosarcoma 30.9 TP53 PTEN NRAS MAP2K1 KIT HRAS
33 connective tissue cancer 30.9 TP53 PTEN CDKN2A AKT1
34 gastric cancer 30.9 TP53 PTEN NRAS MAP2K1 KIT HRAS
35 neurofibromatosis, type i 30.9 TP53 PTEN NRAS MAP2K1 KIT HRAS
36 neurofibroma 30.8 TP53 PTEN MITF KIT ERBB2 CDKN2A
37 li-fraumeni syndrome 30.8 TP53 PTEN HRAS ERBB2 CTNNB1 CDKN2A
38 prostate cancer 30.8 TP53 PTEN PCAT29 MAP2K1 HRAS ERBB2
39 retinitis pigmentosa 30.8 TP53 PTEN MITF KIT HRAS ERBB2
40 brain cancer 30.8 TP53 PTEN NRAS HRAS CTNNB1 BRAF
41 endometrial adenocarcinoma 30.8 TP53 PTEN ERBB2 CTNNB1 CDKN2A AKT1
42 sarcoma 30.8 TP53 NRAS KIT HRAS CTNNB1 CDK4
43 kidney cancer 30.8 TP53 PTEN CDKN2A AKT1
44 small cell carcinoma 30.8 TP53 PTEN KIT ERBB2 CDKN2A
45 ductal carcinoma in situ 30.8 TP53 PTEN ERBB2 CDKN2A AKT1
46 cervical cancer 30.8 TP53 PTEN HRAS ERBB2 CTNNB1 CDKN2A
47 cowden syndrome 30.8 TP53 PTEN HRAS ERBB2 CTNNB1 AKT1
48 skin squamous cell carcinoma 30.8 TP53 HRAS ERBB2 CDKN2A BRAF
49 esophageal cancer 30.8 TP53 PTEN HRAS ERBB2 CTNNB1 CDKN2A
50 liposarcoma 30.8 TP53 PTEN CTNNB1 CDKN2A CDK4

Graphical network of the top 20 diseases related to Skin Melanoma:



Diseases related to Skin Melanoma

Symptoms & Phenotypes for Skin Melanoma

UMLS symptoms related to Skin Melanoma:


pruritus, exanthema

GenomeRNAi Phenotypes related to Skin Melanoma according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.21 HRAS
2 Decreased viability GR00055-A-2 10.21 HRAS
3 Decreased viability GR00107-A-1 10.21 MAP2K1
4 Decreased viability GR00221-A-1 10.21 AKT1 CDKN2A HRAS KIT NRAS
5 Decreased viability GR00221-A-2 10.21 AKT1 HRAS
6 Decreased viability GR00221-A-3 10.21 AKT1 CDKN2A HRAS NRAS ERBB2 MAP2K1
7 Decreased viability GR00221-A-4 10.21 AKT1 CDKN2A ERBB2
8 Decreased viability GR00249-S 10.21 AKT1
9 Decreased viability GR00301-A 10.21 KIT
10 Decreased substrate adherent cell growth GR00193-A-1 9.76 KIT
11 Decreased substrate adherent cell growth GR00193-A-2 9.76 CDK4 KIT
12 Decreased substrate adherent cell growth GR00193-A-3 9.76 BRAF CDK4
13 Decreased substrate adherent cell growth GR00193-A-4 9.76 BRAF CDK4 KIT
14 Decreased cell migration GR00055-A-1 9.56 AKT1 CDK4
15 Decreased cell migration GR00055-A-3 9.56 BRAF HRAS
16 Increased focal adhesion (FA) area, decreased number of small and round FAs, increased peripheral FA formation, increased cell spreading GR00210-A 8.32 CTNNB1

MGI Mouse Phenotypes related to Skin Melanoma:

46 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.54 AKT1 BRAF CDK4 CDKN2A CTNNB1 ERBB2
2 growth/size/body region MP:0005378 10.52 AKT1 BRAF CDK4 CDKN2A CTNNB1 ERBB2
3 cardiovascular system MP:0005385 10.5 AKT1 BRAF CDK4 CDKN2A CTNNB1 ERBB2
4 endocrine/exocrine gland MP:0005379 10.5 AKT1 BRAF CDK4 CDKN2A CTNNB1 ERBB2
5 homeostasis/metabolism MP:0005376 10.5 AKT1 BRAF CDK4 CDKN2A CTNNB1 ERBB2
6 integument MP:0010771 10.48 AKT1 BRAF CDK4 CDKN2A CTNNB1 ERBB2
7 cellular MP:0005384 10.47 AKT1 BRAF CDK4 CDKN2A CTNNB1 ERBB2
8 craniofacial MP:0005382 10.46 BRAF CDK4 CTNNB1 ERBB2 FBN1 GNA11
9 embryo MP:0005380 10.42 AKT1 BRAF CDK4 CDKN2A CTNNB1 ERBB2
10 hematopoietic system MP:0005397 10.42 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
11 mortality/aging MP:0010768 10.41 AKT1 BRAF CDK4 CDKN2A CTNNB1 ERBB2
12 immune system MP:0005387 10.4 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
13 digestive/alimentary MP:0005381 10.35 BRAF CDK4 CDKN2A CTNNB1 ERBB2 HRAS
14 nervous system MP:0003631 10.33 AKT1 BRAF CDK4 CDKN2A CTNNB1 ERBB2
15 limbs/digits/tail MP:0005371 10.31 BRAF CTNNB1 ERBB2 FBN1 GNA11 GNAQ
16 muscle MP:0005369 10.31 AKT1 BRAF CDK4 CDKN2A CTNNB1 ERBB2
17 neoplasm MP:0002006 10.29 AKT1 BRAF CDK4 CDKN2A CTNNB1 ERBB2
18 liver/biliary system MP:0005370 10.26 AKT1 BRAF CDK4 CDKN2A CTNNB1 GNA11
19 normal MP:0002873 10.25 AKT1 BRAF CDK4 CTNNB1 ERBB2 GNA11
20 hearing/vestibular/ear MP:0005377 10.24 BRAF CTNNB1 GNA11 GNAQ KIT MAP2K1
21 pigmentation MP:0001186 10.18 BRAF CDK4 CDKN2A CTNNB1 FBN1 GNA11
22 no phenotypic analysis MP:0003012 10.09 CDKN2A CTNNB1 FBN1 HRAS KIT MC1R
23 renal/urinary system MP:0005367 10.06 BRAF CDK4 CTNNB1 FBN1 GNA11 GNAQ
24 reproductive system MP:0005389 10.03 AKT1 BRAF CDK4 CDKN2A CTNNB1 ERBB2
25 respiratory system MP:0005388 9.93 AKT1 BRAF CDKN2A CTNNB1 ERBB2 FBN1
26 skeleton MP:0005390 9.86 AKT1 BRAF CDK4 CDKN2A CTNNB1 ERBB2
27 vision/eye MP:0005391 9.32 BRAF CDK4 CDKN2A CTNNB1 KIT MAP2K1

Drugs & Therapeutics for Skin Melanoma

Drugs for Skin Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 530)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
2
Vindesine Approved, Investigational Phase 4 53643-48-4, 59917-39-4 40839
3
Etanercept Approved, Investigational Phase 4 185243-69-0
4
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
5
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
6
Pasireotide Approved Phase 4 396091-73-9 9941444
7
Lactitol Approved, Investigational Phase 4 585-86-4 157355
8
Somatostatin Approved, Investigational Phase 4 51110-01-1, 38916-34-6 53481605
9
Cabergoline Approved Phase 4 81409-90-7 54746
10 Triamcinolone hexacetonide Phase 4
11 triamcinolone acetonide Phase 4
12 Triamcinolone diacetate Phase 4
13 Calcineurin Inhibitors Phase 4
14 Hemostatics Phase 4
15 Cyclosporins Phase 4
16 Fibrin Tissue Adhesive Phase 4
17 Coagulants Phase 4
18 Neurotransmitter Agents Phase 4
19 Dopamine Agents Phase 4
20 Hormones Phase 4
21 Hormone Antagonists Phase 4
22 Dopamine agonists Phase 4
23 Antiparkinson Agents Phase 4
24
Treosulfan Approved, Investigational Phase 3 299-75-2 9296
25
Timolol Approved Phase 3 26839-75-8 33624 5478
26
Ranibizumab Approved Phase 3 347396-82-1 459903
27
tannic acid Approved Phase 2, Phase 3 1401-55-4
28
Benzocaine Approved, Investigational Phase 2, Phase 3 1994-09-7, 94-09-7 2337
29
Aminolevulinic acid Approved Phase 3 106-60-5 137
30
Peginterferon alfa-2a Approved, Investigational Phase 3 198153-51-4 5360545
31
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
32
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
33
leucovorin Approved Phase 3 58-05-9 6006
34
Bevacizumab Approved, Investigational Phase 3 216974-75-3
35
BCG vaccine Approved, Investigational Phase 3
36
Peginterferon alfa-2b Approved Phase 2, Phase 3 215647-85-1, 99210-65-8
37
Xylometazoline Approved, Investigational Phase 3 526-36-3 5709
38
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
39
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
40
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 6221 5280795
41
Imidacloprid Vet_approved Phase 3 105827-78-9 86418
42
Fotemustine Investigational Phase 3 92118-27-9
43
Oblimersen Experimental, Investigational Phase 2, Phase 3 190977-41-4
44 Detox adjuvant Phase 3
45 polysaccharide-K Phase 3
46 Photosensitizing Agents Phase 3
47 Methyl 5-aminolevulinate Phase 3
48 Olive Phase 3
49 Pharmaceutical Solutions Phase 2, Phase 3
50 Central Nervous System Stimulants Phase 3

Interventional clinical trials:

(show top 50) (show all 2398)
# Name Status NCT ID Phase Drugs
1 Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies Unknown status NCT02626065 Phase 4 Nivolumab
2 A Randomized Control Trial of Intravitreal Ranibizumab (Lucentis) for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy for Choroidal Melanoma Unknown status NCT00540930 Phase 4 Ranibizumab
3 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy (CVD-Protocol) in the Second-Line Therapy of Distant Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4 Cisplatin, Vindesine, Dacarbazine (drugs)
4 Transpupillary Thermotherapy (TTT) Alone Versus the Combined Therapy Consisting of TTT and Intravitreal Injection of Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Unknown status NCT02379000 Phase 4 Triamcinolone Acetonide
5 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
6 Photodynamic Therapy for Melanoma Precursor Lesion Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion (BF-200 ALA) as a Light Sensitizing Cream Completed NCT02685592 Phase 4 5-aminolevulinic acid nanoemulsion
7 A Randomized, Open-Label Study to Compare the Rate of New Non-Melanoma Skin Cancer in Maintenance Renal Allograft Recipients Converted to a Sirolimus-based Regimen Versus Continuation of a Calcineurin Inhibitor-based Regimen Completed NCT00129961 Phase 4 sirolimus;cyclosporine or tacrolimus
8 An Open-Label, Single-Arm, Multicenter Study To Assess The Safety Of Vemurafenib In Patients With Braf V600 Mutation Positive Metastatic Melanoma In South Africa. Completed NCT01898585 Phase 4 Zelboraf
9 Neoadjuvant GM-CSF Treatment and Modulation of Immune Cell Profile of the SLN in Melanoma Completed NCT02451488 Phase 4 GM-CSF
10 Can Fibrin Sealant be Used to Reduce Post-operative Drainage Following Lymph Node Dissection: a Prospective Randomised Double Blind Trial. Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
11 Elderly Cancer PatIents Treated for Advanced or Metastatic Melanoma or NSCLC, Safety and qualiTy of Life Under immunOtheraPies: a Phase IV Trial Recruiting NCT03673332 Phase 4 immune-checkpoint inhibitors therapies
12 A Prospective, Open-label, Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA®) in Subjects With Unresectable or Metastatic Melanoma or PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) in India (Keynote-593) Recruiting NCT03715205 Phase 4 Pembrolizumab
13 Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
14 Phase IV Ipilimumab in Melanoma: A National, Multicenter, Interventional Study in Patients With Unresectable or Metastatic Melanoma Active, not recruiting NCT02068196 Phase 4 Ipilimumab
15 An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment Active, not recruiting NCT01794793 Phase 4 Pasireotide;Cabergoline;Pasireotide
16 Influenza Vaccine Responses in the Setting of Melanoma Treatment Enrolling by invitation NCT03315975 Phase 4
17 An Exploratory Prospective, Open-label, Unicentric Study With Cross-over Design, Comparing Lymphoseek® vs. Albumin Nanocolloid for Image- Guided Sentinel Lymph Node Mapping in Head and Neck, Melanoma and Breast Cancer. Not yet recruiting NCT04261179 Phase 4 Lymphoseek;Nanocoll
18 Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting Programmed Cell Death 1 (PD-1) Not yet recruiting NCT03313544 Phase 4 Nivolumab
19 Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4 High Dose Interleukin-2;Ipilimumab
20 A Multi-Center Study of High Dose Aldesleukin (Interleukin-2) + Vemurafenib Therapy in Patients With BRAFV600 Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
21 Phase II GENIUS Trial of GENetically-Informed Therapies for Patients With previoUSly Treated Refractory Metastatic Cancer Withdrawn NCT02000739 Phase 4
22 Randomized, Comparative Phase II/III Study Between Treatment With CSF470 Vaccine (Allogeneic, Irradiated) Plus BCG and MOLGRAMOSTIN (rhGM-CSF) as Adjuvants and Interferon-alfa 2b (IFN-ALPHA), in Stages IIB, IIC and III Post Surgery Cutaneous Melanoma Patients Unknown status NCT01729663 Phase 2, Phase 3 interferon alpha 2b
23 Allogeneic Vaccine Modified to Express HLA A2/4-1BB Ligand for High Risk or Low Residual Disease Melanoma Patients Unknown status NCT01861938 Phase 2, Phase 3
24 Comparison of M-Vax Plus Low Dose Interleukin-2 Versus Placebo Vaccine Plus Low Dose Interleukin-2 in Patients With Stage IV Melanoma Unknown status NCT00477906 Phase 3
25 Treatment Of Radiation Retinopathy Trial Subtitle: Treatment of Radiation Retinopathy; Influence of Lucentis® and Kenalog® on Radiation Retinopathy After Irradiation of Choroidal Melanoma. Unknown status NCT00811200 Phase 2, Phase 3 ranibizumab;triamcinolone acetonide
26 Adjuvant Pegylated-Interferon-alpha2b (SylatronTM) for 2 Years Versus Observation in Patients With an Ulcerated Primary Cutaneous Melanoma With T(2-4)bN0M0: a Randomized Phase III Trial of the EORTC Melanoma Group. Unknown status NCT01502696 Phase 3
27 Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination: Post-Operative Adjuvant Ganglioside GM2-KLH/QS-21 (BMS-248479) Vaccination Treatment After Resection of Primary Cutaneous Melanoma Thicker Than 1.5mm (AJCC/UICC Stage II, T3-T4N0M0), a 2-Arm Multicenter Randomized Phase III Trial vs. Observation Unknown status NCT00005052 Phase 3
28 Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With BCG Plus a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Versus BCG Plus a Placebo as a Post-Surgical Treatment for Stage III Melanoma Unknown status NCT00052130 Phase 3
29 A Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Plus BCG Versus Placebo Plus BCG as a Post-Surgical Treatment for Stage IV Melanoma Unknown status NCT00052156 Phase 3
30 A Pivotal Phase III, Open-label, Randomized, Controlled Multi-center Study of the Efficacy of L19IL2/L19TNF Neoadjuvant Intratumoral Treatment Followed by Surgery Versus Surgery Alone in Clinical Stage III B/C Melanoma Patients Unknown status NCT02938299 Phase 3 L19IL2 + L19TNF
31 A Phase III, Multi-Center Controlled Trial With Stratified Randomization Comparing The Efficacy Of Interleukin-2 (IL-2) Plus Histamine Dihydrochloride (HDC) Versus IL-2 Alone To Increase The Duration Of Survival In Patients With AJCC Stage IV Malignant Melanoma With Hepatic Metastasis Unknown status NCT00039234 Phase 3 histamine dihydrochloride
32 PEG-Intron Observation After Regional Lymph Node Dissection in AJCC Stage III (TxN1-2MO) Melanoma Patients: a Randomized Phase III Trial Unknown status NCT00006249 Phase 3
33 PHASE III TRIAL OF MELACINE PLUS INTERFERON ALFA-2B VERSUS INTERFERON ALFA-2B IN PATIENTS WITH DISSEMINATED MALIGNANT MELANOMA Unknown status NCT00002767 Phase 3
34 POST-OPERATIVE ADJUVANT INTERFERON-ALFA-2B (INTRON-A) TREATMENT AFTER RESECTION OF THICK PRIMARY MELANOMA AND/OR REGIONAL LYMPHNODE METASTASES 'INTERMEDIATE-HIGH DOSE' VS INTERMEDIATE-LOW DOSE' IFN-ALFA VS OBSERVATION: A 3-ARM MULTICENTER RANDOMIZED PHASE III TRIAL Unknown status NCT00002763 Phase 3
35 Prospectively Randomized Phase III Study of an Individualized Sensitivity-Directed Combination Chemotherapy Versus DTIC as First-Line Treatment in Stage IV Metastatic Melanoma Unknown status NCT00779714 Phase 3 DTIC (dacarbazine);paclitaxel + cisplatin;treosulfan + cytarabine
36 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
37 Randomized, Multicenter Study for Adjuvant Treatment of Stage III Malignant Melanoma: Intermittent, High-Dose Intravenous Interferon Alpha-2b Versus Standard High-Dose Interferon Alpha-2b Therapy Unknown status NCT00226408 Phase 3 Interferon-alpha-2b
38 Randomized Phase III Study Comparing an Adjuvant Chemotherapy With Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma Unknown status NCT02843386 Phase 3 Adjuvant chemotherapy by Fotemustin
39 A Randomized, Phase III Study of Fotemustine Versus the Combination of Fotemustine and Ipilimumab or the Combination of Ipilimumab and Nivolumab in Patients With Metastatic Melanoma With Brain Metastasis Unknown status NCT02460068 Phase 3 Fotemustine;Fotemustine and Ipilimumab;Ipilimumab and nivolumab
40 A Multicenter, Randomized, Controlled, Phase III Trial Comparing High-Dose IFN-a2b With Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma Unknown status NCT03435302 Phase 3 Temozolomide Plus Cisplatin;High-Dose IFN-a2b
41 Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel Unknown status NCT01272609 Phase 3 Timolol + LCP
42 Immunotherapy of Colon Cancer With Autologous Perchloric Soluble Tumors Extracts Unknown status NCT00002455 Phase 3
43 Phase III Randomized Study of Dacarbazine With or Without Allovectin-7 in Patients With Metastatic Melanoma Completed NCT00003647 Phase 3 allovectin-7;allovectin-7/dacarbazine;dacarbazine
44 TIL (Tumor Infiltrating Lymphocytes) and IL2 (Interleukin 2) Versus Abstention as Adjuvant Treatment in Melanoma With Only One Invaded Lymphnode After Lymphnodes Excision Completed NCT00200577 Phase 3 TIL + IL2
45 A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma Completed NCT01227889 Phase 3 GSK2118436;Dacarbazine (DTIC)
46 A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination With a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2*0201-Positive Patients With Previously Treated Unresectable Stage III or IV Melanoma Completed NCT00094653 Phase 3 MDX-010 (anti-CTLA4) monoclonal antibody
47 A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping Completed NCT00671918 Phase 3 Lymphoseek
48 A Phase III, Double-Blind, Placebo-Controlled Study of Vemurafenib Versus Vemurafenib Plus GDC-0973 in Previously Untreated BRAF^600-Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma Completed NCT01689519 Phase 3 Placebo;Vemurafenib;Cobimetinib
49 The NEMO Trial (NRAS Melanoma and MEK Inhibitor):A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma Completed NCT01763164 Phase 3 MEK162;Dacarbazine
50 A Random-Assignment Study of Hepatic Arterial Infusion of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) (Delcath System) Versus Best Alternative Care for Ocular and Cutaneous Melanoma Metastatic to the Liver Completed NCT00324727 Phase 3 melphalan;regional chemotherapy;systemic chemotherapy

Search NIH Clinical Center for Skin Melanoma

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Aldesleukin
Carmustine
dabrafenib
Dacarbazine
docetaxel
hydroxyurea
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
Lomustine
peginterferon alfa-2a
peginterferon alfa-2b
pembrolizumab
Procarbazine
Procarbazine Hydrochloride
Recombinant interferon beta-1a
Recombinant interferon beta-1b
temozolomide
trametinib
Vemurafenib

Cochrane evidence based reviews: melanoma, cutaneous malignant

Genetic Tests for Skin Melanoma

Anatomical Context for Skin Melanoma

MalaCards organs/tissues related to Skin Melanoma:

40
Skin, Lymph Node, T Cells, Liver, Breast, Brain, Lung

Publications for Skin Melanoma

Articles related to Skin Melanoma:

(show top 50) (show all 7983)
# Title Authors PMID Year
1
Codon-specific translation reprogramming promotes resistance to targeted therapy. 6
29925953 2018
2
A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. 6
28854169 2017
3
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. 6
25079330 2014
4
Copper is required for oncogenic BRAF signalling and tumorigenesis. 6
24717435 2014
5
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. 6
24670642 2014
6
Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas. 6
24512911 2014
7
A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. 6
23685455 2013
8
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. 6
23302800 2013
9
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. 6
22281684 2012
10
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). 6
22113612 2011
11
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. 6
21107320 2010
12
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. 6
21107323 2010
13
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. 6
20823850 2010
14
Inhibition of mutated, activated BRAF in metastatic melanoma. 6
20818844 2010
15
New common variants affecting susceptibility to basal cell carcinoma. 6
19578363 2009
16
SLC45A2: a novel malignant melanoma-associated gene. 6
18563784 2008
17
Variants of the MATP/SLC45A2 gene are protective for melanoma in the French population. 6
18683857 2008
18
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. 6
18398503 2008
19
A genomewide association study of skin pigmentation in a South Asian population. 6
17999355 2007
20
Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. 6
17785355 2007
21
BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. 6
17488796 2007
22
BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. 6
17374713 2007
23
Distribution of the F374 allele of the SLC45A2 (MATP) gene and founder-haplotype analysis. 6
17044855 2006
24
Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. 6
16772349 2006
25
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. 6
16174717 2005
26
High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. 6
15998781 2005
27
BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. 6
16015629 2005
28
High incidence of thyroid cancer in long-standing goiters with thyroglobulin mutations. 6
16187918 2005
29
Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. 6
15687339 2005
30
Mutations of BRAF and RAS are rare events in germ cell tumours. 6
15386408 2005
31
BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. 6
15342696 2004
32
Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. 6
15356022 2004
33
Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. 6
15181070 2004
34
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. 6
15126572 2004
35
BRAF T1796A transversion mutation in various thyroid neoplasms. 6
15001635 2004
36
Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. 6
14513361 2003
37
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. 6
14602780 2003
38
Exclusion of BRAFV599E as a melanoma susceptibility mutation. 6
12794760 2003
39
BRAF mutations in metastatic melanoma: a possible association with clinical outcome. 6
12960123 2003
40
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. 6
12670889 2003
41
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. 6
12644542 2003
42
Absence of exon 15 BRAF germline mutations in familial melanoma. 6
12619120 2003
43
High frequency of BRAF mutations in nevi. 6
12447372 2003
44
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. 6
12198537 2002
45
Mutations of the BRAF gene in human cancer. 6
12068308 2002
46
Identification of PTEN mutations in metastatic melanoma specimens. 6
10978354 2000
47
Mutation and homozygous deletion analyses of genes that control the G1/S transition of the cell cycle in skin melanoma: p53, p21, p16 and p15. 54 61
15960923 2005
48
The loss of NM23 protein in malignant melanoma predicts lymphatic spread without affecting survival. 61 54
11268486 2000
49
Differential expression of nm23 H-1 protein in conjunctival melanoma and potential precursor lesions. 54 61
10620396 1999
50
[Prognosis and invasion marker expression of cutaneous melanoma. Metastasis-associated genes (nm23, CD44v3, MMP2]. 61 54
10064977 1999

Variations for Skin Melanoma

ClinVar genetic disease variations for Skin Melanoma:

6 (show top 50) (show all 455)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 SLC45A2 NM_016180.5(SLC45A2):c.1122= (p.Leu374=) SNV protective 4505 rs16891982 5:33951693-33951693 5:33951588-33951588
2 PTEN NM_000314.7(PTEN):c.649G>A (p.Val217Ile) SNV Pathogenic 7838 rs121909234 10:89717624-89717624 10:87957867-87957867
3 MAP2K1 NM_002755.3(MAP2K1):c.607G>A (p.Glu203Lys) SNV Pathogenic 375982 rs1057519733 15:66774131-66774131 15:66481793-66481793
4 NRAS NM_002524.5(NRAS):c.38G>C (p.Gly13Ala) SNV Pathogenic 375877 rs121434596 1:115258744-115258744 1:114716123-114716123
5 BRAF NM_004333.6(BRAF):c.1798_1799delinsAA (p.Val600Lys) Indel Pathogenic 375941 rs121913227 7:140453136-140453137 7:140753336-140753337
6 BRAF NM_004333.6(BRAF):c.1799_1800delinsAT (p.Val600Asp) Indel Pathogenic 375939 rs121913377 7:140453135-140453136 7:140753335-140753336
7 BRAF NM_001374258.1(BRAF):c.1918G>A (p.Val640Met) SNV Pathogenic 44815 rs121913378 7:140453137-140453137 7:140753337-140753337
8 BRAF NM_004333.6(BRAF):c.1798_1799delinsAG (p.Val600Arg) Indel Pathogenic 375940 rs121913227 7:140453136-140453137 7:140753336-140753337
9 NRAS NM_002524.5(NRAS):c.35G>A (p.Gly12Asp) SNV Pathogenic 39648 rs121913237 1:115258747-115258747 1:114716126-114716126
10 NRAS NM_002524.5(NRAS):c.37G>T (p.Gly13Cys) SNV Pathogenic 40471 rs121434595 1:115258745-115258745 1:114716124-114716124
11 PTEN NM_000314.8(PTEN):c.633C>A SNV Pathogenic 7836 rs121909232 10:89712015-89712015 10:87952258-87952258
12 NRAS NM_002524.5(NRAS):c.35G>T (p.Gly12Val) SNV Pathogenic 40470 rs121913237 1:115258747-115258747 1:114716126-114716126
13 KIT NM_000222.2(KIT):c.1676T>A (p.Val559Asp) SNV Pathogenic 13856 rs121913517 4:55593610-55593610 4:54727444-54727444
14 KIT NM_000222.2(KIT):c.1965T>A (p.Asn655Lys) SNV Pathogenic 375923 rs1057519708 4:55594262-55594262 4:54728096-54728096
15 NRAS NM_002524.5(NRAS):c.182_183delinsTG (p.Gln61Leu) Indel Pathogenic 375872 rs1057519695 1:115256528-115256529 1:114713907-114713908
16 BRAF NM_004333.6(BRAF):c.1789_1790delinsTC (p.Leu597Ser) Indel Pathogenic 375942 rs121913368 7:140453145-140453146 7:140753345-140753346
17 MAP2K1 NM_002755.4(MAP2K1):c.1144A>C (p.Asn382His) SNV Pathogenic 375984 rs1057519735 15:66782915-66782915 15:66490577-66490577
18 MAP2K1 NM_002755.3(MAP2K1):c.157T>C (p.Phe53Leu) SNV Pathogenic 375977 rs1057519728 15:66727441-66727441 15:66435103-66435103
19 MAP2K1 NM_002755.3(MAP2K1):c.332T>G (p.Ile111Ser) SNV Pathogenic 375979 rs1057519730 15:66729124-66729124 15:66436786-66436786
20 MAP2K1 NM_002755.3(MAP2K1):c.790C>T (p.Pro264Ser) SNV Pathogenic 375983 rs1057519734 15:66777424-66777424 15:66485086-66485086
21 BRAF NM_004333.6(BRAF):c.1782T>A (p.Asp594Glu) SNV Pathogenic 375945 rs121913337 7:140453153-140453153 7:140753353-140753353
22 NRAS NM_002524.5(NRAS):c.182_183delinsGG (p.Gln61Arg) Indel Pathogenic 375873 rs1057519695 1:115256528-115256529 1:114713907-114713908
23 BRAF NM_004333.6(BRAF):c.1779_1780delinsGA (p.Asp594Asn) Indel Pathogenic 375948 rs1057519718 7:140453155-140453156 7:140753355-140753356
24 NRAS NM_002524.5(NRAS):c.181C>G (p.Gln61Glu) SNV Pathogenic 375875 rs121913254 1:115256530-115256530 1:114713909-114713909
25 KIT NM_000222.2(KIT):c.1676T>G (p.Val559Gly) SNV Pathogenic 375912 rs121913517 4:55593610-55593610 4:54727444-54727444
26 KIT NM_000222.2(KIT):c.1679T>A (p.Val560Asp) SNV Pathogenic 375914 rs121913521 4:55593613-55593613 4:54727447-54727447
27 KIT NM_000222.2(KIT):c.1679T>G (p.Val560Gly) SNV Pathogenic 375916 rs121913521 4:55593613-55593613 4:54727447-54727447
28 KIT NM_000222.2(KIT):c.2485G>C (p.Ala829Pro) SNV Pathogenic 375933 rs1057519713 4:55602664-55602664 4:54736498-54736498
29 CTNNB1 NM_001904.4(CTNNB1):c.134C>A (p.Ser45Tyr) SNV Pathogenic 375895 rs121913409 3:41266137-41266137 3:41224646-41224646
30 KIT NM_000222.2(KIT):c.1650A>T (p.Lys550Asn) SNV Pathogenic 375906 rs1057519703 4:55593584-55593584 4:54727418-54727418
31 KIT NM_000222.2(KIT):c.1669T>A (p.Trp557Arg) SNV Pathogenic 375908 rs121913235 4:55593603-55593603 4:54727437-54727437
32 NRAS NM_002524.5(NRAS):c.38G>T (p.Gly13Val) SNV Pathogenic 375876 rs121434596 1:115258744-115258744 1:114716123-114716123
33 NRAS NM_002524.5(NRAS):c.37G>C (p.Gly13Arg) SNV Pathogenic 13899 rs121434595 1:115258745-115258745 1:114716124-114716124
34 GNAQ NM_002072.5(GNAQ):c.626A>C (p.Gln209Pro) SNV Pathogenic 375957 rs121913492 9:80409488-80409488 9:77794572-77794572
35 GNA11 NM_002067.5(GNA11):c.626A>T (p.Gln209Leu) SNV Pathogenic 376002 rs1057519742 19:3118942-3118942 19:3118944-3118944
36 GNA11 NM_002067.5(GNA11):c.626A>C (p.Gln209Pro) SNV Pathogenic 376001 rs1057519742 19:3118942-3118942 19:3118944-3118944
37 BRAF NM_001374258.1(BRAF):c.1909C>G (p.Leu637Val) SNV Pathogenic 13969 rs121913369 7:140453146-140453146 7:140753346-140753346
38 KIT NM_000222.2(KIT):c.1727T>C (p.Leu576Pro) SNV Pathogenic 375919 rs121913513 4:55593661-55593661 4:54727495-54727495
39 BRAF NM_001374258.1(BRAF):c.1901A>G (p.Asp634Gly) SNV Pathogenic 13972 rs121913338 7:140453154-140453154 7:140753354-140753354
40 GNAQ NM_002072.5(GNAQ):c.626A>T (p.Gln209Leu) SNV Pathogenic 375955 rs121913492 9:80409488-80409488 9:77794572-77794572
41 KIT NM_000222.2(KIT):c.2458G>C (p.Asp820His) SNV Pathogenic 375927 rs1057519710 4:55599332-55599332 4:54733166-54733166
42 KIT NM_000222.3(KIT):c.2466T>G SNV Pathogenic 375932 rs121913514 4:55599340-55599340 4:54733174-54733174
43 KIT NM_000222.2(KIT):c.1965T>G (p.Asn655Lys) SNV Pathogenic 375924 rs1057519708 4:55594262-55594262 4:54728096-54728096
44 BRAF NM_004333.6(BRAF):c.1782T>G (p.Asp594Glu) SNV Pathogenic 375944 rs121913337 7:140453153-140453153 7:140753353-140753353
45 KIT NM_000222.2(KIT):c.1510T>C (p.Phe504Leu) SNV Pathogenic 375904 rs1057519702 4:55592186-55592186 4:54726020-54726020
46 KIT NM_000222.2(KIT):c.1961T>C (p.Val654Ala) SNV Pathogenic 375921 rs121913523 4:55594258-55594258 4:54728092-54728092
47 KIT NM_000222.3(KIT):c.2446G>C SNV Pathogenic 13863 rs121913506 4:55599320-55599320 4:54733154-54733154
48 NRAS NM_002524.5(NRAS):c.38G>A (p.Gly13Asp) SNV Pathogenic 13901 rs121434596 1:115258744-115258744 1:114716123-114716123
49 NRAS NM_002524.5(NRAS):c.34G>A (p.Gly12Ser) SNV Pathogenic 177778 rs121913250 1:115258748-115258748 1:114716127-114716127
50 KIT NM_000222.2(KIT):c.1679T>C (p.Val560Ala) SNV Pathogenic 375915 rs121913521 4:55593613-55593613 4:54727447-54727447

Cosmic variations for Skin Melanoma:

9 (show top 50) (show all 4660)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM95964482 ZNF451 skin,neck,malignant melanoma,NS c.2114T>G p.I705S 6:57148199-57148199 15
2 COSM96588509 ZNF451 skin,neck,malignant melanoma,NS c.2114T>G p.I705S 6:57148199-57148199 15
3 COSM119021797 ZNF451 skin,neck,malignant melanoma,NS c.2114T>G p.I705S 6:57148199-57148199 15
4 COSM84509782 ZNF276 skin,scalp,malignant melanoma,NS c.*1273G>A p.? 16:89739519-89739519 15
5 COSM143038077 YAP1 skin,neck,malignant melanoma,NS c.1303C>T p.Q435* 11:102229716-102229716 15
6 COSM128448849 YAP1 skin,neck,malignant melanoma,NS c.1129C>T p.Q377* 11:102229716-102229716 15
7 COSM145025271 YAP1 skin,neck,malignant melanoma,NS c.1141C>T p.Q381* 11:102229716-102229716 15
8 COSM127995004 YAP1 skin,neck,malignant melanoma,NS c.1243C>T p.Q415* 11:102229716-102229716 15
9 COSM133269851 YAP1 skin,neck,malignant melanoma,NS c.1255C>T p.Q419* 11:102229716-102229716 15
10 COSM126969981 YAP1 skin,neck,malignant melanoma,NS c.757C>T p.Q253* 11:102229716-102229716 15
11 COSM90944416 YAP1 skin,neck,malignant melanoma,NS c.1189C>T p.Q397* 11:102229716-102229716 15
12 COSM85233895 YAP1 skin,neck,malignant melanoma,NS c.1291C>T p.Q431* 11:102229716-102229716 15
13 COSM105837553 XRCC6 skin,scalp,malignant melanoma,NS c.88C>T p.R30* 22:41636155-41636155 15
14 COSM97229917 XRCC6 skin,scalp,malignant melanoma,NS c.1054C>T p.P352S 22:41650816-41650816 15
15 COSM105840182 XRCC6 skin,scalp,malignant melanoma,NS c.1272-1G>T p.? 22:41658251-41658251 15
16 COSM103711614 XRCC6 skin,scalp,malignant melanoma,NS c.1299-1G>T p.? 22:41658251-41658251 15
17 COSM95163322 XRCC6 skin,scalp,malignant melanoma,NS c.238C>T p.R80* 22:41636155-41636155 15
18 COSM95165917 XRCC6 skin,scalp,malignant melanoma,NS c.1054C>T p.P352S 22:41650816-41650816 15
19 COSM108016980 XRCC6 skin,scalp,malignant melanoma,NS c.904C>T p.P302S 22:41650816-41650816 15
20 COSM103707744 XRCC6 skin,scalp,malignant melanoma,NS c.196-81C>T p.? 22:41636155-41636155 15
21 COSM103710325 XRCC6 skin,scalp,malignant melanoma,NS c.931C>T p.P311S 22:41650816-41650816 15
22 COSM97227877 XRCC6 skin,scalp,malignant melanoma,NS c.238C>T p.R80* 22:41636155-41636155 15
23 COSM108015015 XRCC6 skin,scalp,malignant melanoma,NS c.88C>T p.R30* 22:41636155-41636155 15
24 COSM95166966 XRCC6 skin,scalp,malignant melanoma,NS c.1422-1G>T p.? 22:41658251-41658251 15
25 COSM106337870 XRCC6 skin,scalp,malignant melanoma,NS c.1422-1G>T p.? 22:41658251-41658251 15
26 COSM108018036 XRCC6 skin,scalp,malignant melanoma,NS c.1272-1G>T p.? 22:41658251-41658251 15
27 COSM97231271 XRCC6 skin,scalp,malignant melanoma,NS c.1422-1G>T p.? 22:41658251-41658251 15
28 COSM106334939 XRCC6 skin,scalp,malignant melanoma,NS c.238C>T p.R80* 22:41636155-41636155 15
29 COSM106336809 XRCC6 skin,scalp,malignant melanoma,NS c.1054C>T p.P352S 22:41650816-41650816 15
30 COSM105839222 XRCC6 skin,scalp,malignant melanoma,NS c.904C>T p.P302S 22:41650816-41650816 15
31 COSM111540596 WT1 skin,scalp,malignant melanoma,NS c.742G>A p.D248N 11:32428524-32428524 15
32 COSM111525675 WT1 skin,neck,malignant melanoma,NS c.1322G>A p.R441Q 11:32392031-32392031 15
33 COSM113471589 WT1 skin,neck,malignant melanoma,NS c.1373G>A p.R458Q 11:32392031-32392031 15
34 COSM100766084 WT1 skin,scalp,malignant melanoma,NS c.847G>A p.E283K 11:32389120-32389120 15
35 COSM148571624 WT1 skin,scalp,malignant melanoma,NS c.1024G>A p.D342N 11:32400022-32400022 15
36 COSM91384800 WT1 skin,scalp,malignant melanoma,NS c.732C>T p.F244= 11:32428534-32428534 15
37 COSM147420112 WT1 skin,scalp,malignant melanoma,NS c.990C>T p.P330= 11:32400005-32400005 15
38 COSM111523859 WT1 skin,scalp,malignant melanoma,NS c.855G>A p.L285= 11:32427973-32427973 15
39 COSM149724575 WT1 skin,neck,malignant melanoma,NS c.1373G>A p.R458Q 11:32392031-32392031 15
40 COSM111534369 WT1 skin,scalp,malignant melanoma,NS c.1397G>A p.W466* 11:32389155-32389155 15
41 COSM148573419 WT1 skin,scalp,malignant melanoma,NS c.1483G>A p.E495K 11:32389120-32389120 15
42 COSM113486484 WT1 skin,scalp,malignant melanoma,NS c.742G>A p.D248N 11:32428524-32428524 15
43 COSM100765008 WT1 skin,scalp,malignant melanoma,NS c.219G>A p.L73= 11:32427973-32427973 15
44 COSM91378277 WT1 skin,scalp,malignant melanoma,NS c.1457G>A p.W486* 11:32389155-32389155 15
45 COSM148575284 WT1 skin,neck,malignant melanoma,NS c.1373G>A p.R458Q 11:32392031-32392031 15
46 COSM130514531 WT1 skin,scalp,malignant melanoma,NS c.770G>A p.W257* 11:32389155-32389155 15
47 COSM100776282 WT1 skin,scalp,malignant melanoma,NS c.405C>T p.P135= 11:32400005-32400005 15
48 COSM113480145 WT1 skin,scalp,malignant melanoma,NS c.1041C>T p.P347= 11:32400005-32400005 15
49 COSM130505084 WT1 skin,scalp,malignant melanoma,NS c.337G>A p.D113N 11:32400022-32400022 15
50 COSM148586611 WT1 skin,scalp,malignant melanoma,NS c.1041C>T p.P347= 11:32400005-32400005 15

Expression for Skin Melanoma

Search GEO for disease gene expression data for Skin Melanoma.

Pathways for Skin Melanoma

Pathways related to Skin Melanoma according to GeneCards Suite gene sharing:

(show top 50) (show all 160)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.32 TP53 PTEN NRAS MC1R MAP2K1 KIT
2
Show member pathways
13.98 TP53 PTEN NRAS MAP2K1 KIT HRAS
3
Show member pathways
13.95 TP53 PTEN NRAS MAP2K1 KIT HRAS
4
Show member pathways
13.87 TP53 NRAS MAP2K1 KIT HRAS GNA11
5
Show member pathways
13.81 TP53 NRAS MAP2K1 KIT HRAS GNA11
6
Show member pathways
13.71 NRAS MAP2K1 KIT HRAS GNA11 ERBB2
7
Show member pathways
13.69 TP53 NRAS MAP2K1 KIT HRAS GNA11
8
Show member pathways
13.65 NRAS MAP2K1 KIT HRAS ERBB2 CTNNB1
9
Show member pathways
13.59 TP53 NRAS MAP2K1 HRAS GNAQ CTNNB1
10
Show member pathways
13.57 PTEN NRAS MAP2K1 HRAS GNA11 FBN1
11
Show member pathways
13.55 TP53 PTEN NRAS KIT HRAS GNA11
12
Show member pathways
13.51 TP53 NRAS MAP2K1 KIT HRAS ERBB2
13
Show member pathways
13.48 PTEN NRAS MAP2K1 KIT HRAS GNA11
14
Show member pathways
13.44 NRAS MAP2K1 KIT HRAS ERBB2 CTNNB1
15
Show member pathways
13.43 PTEN NRAS KIT HRAS ERBB2 CTNNB1
16
Show member pathways
13.4 TP53 PTEN NRAS MAP2K1 HRAS GNAQ
17
Show member pathways
13.26 TP53 PTEN NRAS MAP2K1 HRAS GNAQ
18
Show member pathways
13.24 TP53 PTEN NRAS MAP2K1 KIT HRAS
19
Show member pathways
13.23 TP53 NRAS MAP2K1 HRAS GNAQ GNA11
20
Show member pathways
13.22 NRAS MAP2K1 HRAS GNA11 CTNNB1 CDKN2A
21
Show member pathways
13.18 NRAS MAP2K1 KIT HRAS GNA11 AKT1
22
Show member pathways
13.18 TP53 NRAS MAP2K1 HRAS GNA11 CTNNB1
23
Show member pathways
13.14 TP53 PTEN NRAS MAP2K1 KIT HRAS
24
Show member pathways
13.12 PTEN NRAS MAP2K1 HRAS CTNNB1 CDK4
25
Show member pathways
13.09 PTEN NRAS MAP2K1 HRAS ERBB2 CTNNB1
26
Show member pathways
13.08 PTEN NRAS MAP2K1 HRAS ERBB2 BRAF
27
Show member pathways
13.07 NRAS MAP2K1 HRAS GNAQ GNA11 BRAF
28
Show member pathways
13.07 TP53 NRAS MAP2K1 HRAS GNAQ GNA11
29
Show member pathways
13.06 PTEN NRAS MAP2K1 HRAS GNA11 ERBB2
30
Show member pathways
13.03 NRAS MAP2K1 KIT HRAS GNAQ GNA11
31
Show member pathways
13 NRAS MAP2K1 HRAS GNA11 CTNNB1 BRAF
32
Show member pathways
12.98 NRAS MITF MC1R MAP2K1 KIT HRAS
33 12.95 TP53 NRAS MAP2K1 KIT HRAS ERBB2
34
Show member pathways
12.94 NRAS MAP2K1 HRAS GNAQ GNA11 AKT1
35
Show member pathways
12.92 TP53 PTEN NRAS KIT HRAS ERBB2
36
Show member pathways
12.92 NRAS MAP2K1 KIT HRAS GNAQ CTNNB1
37
Show member pathways
12.89 PTEN MAP2K1 HRAS BRAF AKT1
38
Show member pathways
12.89 TP53 PTEN NRAS MAP2K1 KIT HRAS
39
Show member pathways
12.88 TP53 NRAS MAP2K1 HRAS CDKN2A AKT1
40
Show member pathways
12.87 TP53 PTEN NRAS MAP2K1 HRAS ERBB2
41
Show member pathways
12.85 NRAS MAP2K1 HRAS GNAQ GNA11 AKT1
42
Show member pathways
12.85 TP53 NRAS MAP2K1 HRAS BRAF AKT1
43
Show member pathways
12.85 NRAS MAP2K1 HRAS GNAQ GNA11 CTNNB1
44
Show member pathways
12.84 NRAS MAP2K1 HRAS GNA11 BRAF AKT1
45
Show member pathways
12.82 TP53 PTEN NRAS MAP2K1 HRAS ERBB2
46
Show member pathways
12.79 PTEN NRAS MAP2K1 HRAS CDK4 AKT1
47
Show member pathways
12.77 TP53 NRAS HRAS ERBB2 CTNNB1 AKT1
48
Show member pathways
12.75 TP53 PTEN NRAS MITF MAP2K1 HRAS
49 12.74 TP53 PTEN NRAS MAP2K1 HRAS ERBB2
50
Show member pathways
12.73 PTEN NRAS MAP2K1 HRAS AKT1

GO Terms for Skin Melanoma

Cellular components related to Skin Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.5 TP53 PTEN MITF MC1R MAP2K1 KIT
2 protein-containing complex GO:0032991 9.43 TP53 MITF CTNNB1 CDKN2A CDK4 AKT1

Biological processes related to Skin Melanoma according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.21 TP53 MITF MC1R HRAS CTNNB1 CDKN2A
2 positive regulation of transcription, DNA-templated GO:0045893 10.12 TP53 MITF MAP2K1 CTNNB1 CDKN2A AKT1
3 protein phosphorylation GO:0006468 10.09 MAP2K1 KIT ERBB2 CDK4 BRAF AKT1
4 intracellular signal transduction GO:0035556 10.07 MC1R KIT ERBB2 BRAF AKT1
5 negative regulation of apoptotic process GO:0043066 10.03 TP53 PTEN MITF CTNNB1 BRAF AKT1
6 phosphorylation GO:0016310 10.02 MAP2K1 KIT ERBB2 CDKN2A CDK4 BRAF
7 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.98 PTEN MAP2K1 HRAS BRAF
8 negative regulation of gene expression GO:0010629 9.98 TP53 MAP2K1 HRAS CTNNB1 AKT1
9 negative regulation of cell proliferation GO:0008285 9.97 TP53 PTEN MAP2K1 HRAS CTNNB1 CDKN2A
10 protein stabilization GO:0050821 9.96 TP53 PTEN GNAQ CDKN2A
11 positive regulation of cell proliferation GO:0008284 9.95 PTEN KIT HRAS ERBB2 CTNNB1 CDK4
12 signal transduction GO:0007165 9.93 NRAS MC1R MAP2K1 KIT HRAS GNAQ
13 positive regulation of apoptotic process GO:0043065 9.91 TP53 PTEN CTNNB1 CDKN2A CDK4 AKT1
14 peptidyl-tyrosine phosphorylation GO:0018108 9.89 MAP2K1 KIT ERBB2 BRAF
15 cell cycle arrest GO:0007050 9.88 TP53 MAP2K1 HRAS CDKN2A
16 cellular response to growth factor stimulus GO:0071363 9.85 ERBB2 CTNNB1 AKT1
17 positive regulation of MAPK cascade GO:0043410 9.85 KIT HRAS ERBB2 CTNNB1
18 MAPK cascade GO:0000165 9.85 NRAS MAP2K1 KIT HRAS ERBB2 BRAF
19 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.84 PTEN CDKN2A CDK4
20 positive regulation of DNA-binding transcription factor activity GO:0051091 9.84 PTEN KIT CTNNB1 AKT1
21 positive regulation of MAP kinase activity GO:0043406 9.82 KIT HRAS ERBB2
22 thymus development GO:0048538 9.8 MAP2K1 CTNNB1 BRAF
23 cellular response to nerve growth factor stimulus GO:1990090 9.78 PTEN BRAF AKT1
24 phosphatidylinositol 3-kinase signaling GO:0014065 9.77 PTEN ERBB2 AKT1
25 Ras protein signal transduction GO:0007265 9.76 TP53 NRAS HRAS CDKN2A
26 pigmentation GO:0043473 9.74 MITF MC1R KIT
27 regulation of cell proliferation GO:0042127 9.73 TP53 MITF KIT CTNNB1 CDK4 BRAF
28 developmental pigmentation GO:0048066 9.69 KIT GNA11
29 negative regulation of cell size GO:0045792 9.69 PTEN AKT1
30 cellular senescence GO:0090398 9.69 MAP2K1 HRAS CDKN2A
31 cellular response to insulin-like growth factor stimulus GO:1990314 9.68 PTEN FBN1
32 somatic stem cell division GO:0048103 9.68 KIT CDKN2A
33 phototransduction, visible light GO:0007603 9.68 GNAQ GNA11
34 positive regulation of DNA-templated transcription, initiation GO:2000144 9.65 MITF CTNNB1
35 entrainment of circadian clock GO:0009649 9.65 GNAQ GNA11
36 trachea formation GO:0060440 9.64 MAP2K1 CTNNB1
37 myeloid progenitor cell differentiation GO:0002318 9.63 KIT BRAF
38 negative regulation of immature T cell proliferation in thymus GO:0033088 9.63 ERBB2 CDKN2A
39 cellular response to decreased oxygen levels GO:0036294 9.61 PTEN AKT1
40 canonical Wnt signaling pathway involved in negative regulation of apoptotic process GO:0044336 9.52 MITF CTNNB1
41 regulation of axon regeneration GO:0048679 9.5 PTEN MAP2K1 BRAF
42 heart development GO:0007507 9.5 TP53 PTEN MAP2K1 GNA11 FBN1 ERBB2
43 positive regulation of gene expression GO:0010628 9.36 TP53 PTEN MITF MAP2K1 KIT HRAS

Molecular functions related to Skin Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.88 TP53 PTEN CTNNB1 CDKN2A AKT1
2 protein-containing complex binding GO:0044877 9.8 NRAS HRAS FBN1 CDK4 BRAF
3 protein C-terminus binding GO:0008022 9.73 MAP2K1 HRAS ERBB2 CTNNB1
4 protein kinase activity GO:0004672 9.63 MAP2K1 KIT ERBB2 CDK4 BRAF AKT1
5 protein tyrosine kinase activity GO:0004713 9.56 MAP2K1 KIT ERBB2 BRAF
6 disordered domain specific binding GO:0097718 9.5 TP53 CTNNB1 CDKN2A
7 kinase activity GO:0016301 9.5 MAP2K1 KIT ERBB2 CDKN2A CDK4 BRAF
8 MDM2/MDM4 family protein binding GO:0097371 9.46 TP53 CDKN2A
9 type 2A serotonin receptor binding GO:0031826 9.37 GNAQ GNA11
10 nucleotide binding GO:0000166 9.32 NRAS MAP2K1 KIT HRAS GNAQ GNA11

Sources for Skin Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....